Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUSION I: Serial Nesiritide Infusions in CHF
NCT00270361Phase 3Completed
- Sponsor
- Scios Inc.
- Start
- Dec 2001
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of nesiritide in heart failure (HF) (3 arms), sponsored by Scios Inc. Primary endpoint: Safety and tolerability of treatment of nesiritide at 12 weeks. Started Dec 2001; status: completed.
02
Drugs
nesiritide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00270361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270361.